These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23143981)

  • 1. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy.
    Wilkie KP
    Adv Exp Med Biol; 2013; 734():201-34. PubMed ID: 23143981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifaceted kinetics of immuno-evasion from tumor dormancy.
    d'Onofrio A
    Adv Exp Med Biol; 2013; 734():111-43. PubMed ID: 23143978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor dormancy and cancer stem cells: two sides of the same coin?
    Kleffel S; Schatton T
    Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy.
    Wilkie KP; Hahnfeldt P
    Cancer Res; 2013 Jun; 73(12):3534-44. PubMed ID: 23536560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical model reveals how regulating the three phases of T-cell response could counteract immune evasion.
    Lorenzi T; Chisholm RH; Melensi M; Lorz A; Delitala M
    Immunology; 2015 Oct; 146(2):271-80. PubMed ID: 26119966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor dormancy and immunoescape.
    Quesnel B
    APMIS; 2008; 116(7-8):685-94. PubMed ID: 18834412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of the cell-mediated immune response to tumour growth.
    López ÁG; Seoane JM; Sanjuán MAF
    Philos Trans A Math Phys Eng Sci; 2017 Jun; 375(2096):. PubMed ID: 28507236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the Immune Response to Cancer: An Individual-Based Approach Accounting for the Difference in Movement Between Inactive and Activated T Cells.
    Macfarlane FR; Lorenzi T; Chaplain MAJ
    Bull Math Biol; 2018 Jun; 80(6):1539-1562. PubMed ID: 29536427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fundamental role of mechanical properties in the progression of cancer disease and inflammation.
    Mierke CT
    Rep Prog Phys; 2014 Jul; 77(7):076602. PubMed ID: 25006689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One?
    Kareva I; Luddy KA; O'Farrelly C; Gatenby RA; Brown JS
    Front Immunol; 2021; 12():668221. PubMed ID: 34531851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunotherapy on the response of TICLs to solid tumour invasion.
    Mambili-Mamboundou H; Sibanda P; Malinzi J
    Math Biosci; 2014 Mar; 249():52-9. PubMed ID: 24480736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer.
    Romero I; Garrido F; Garcia-Lora AM
    Cancer Res; 2014 Dec; 74(23):6750-7. PubMed ID: 25411345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fresh look at tumor immunosurveillance and immunotherapy.
    Smyth MJ; Godfrey DI; Trapani JA
    Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stochastic modeling of tumor progression and immune evasion.
    George JT; Levine H
    J Theor Biol; 2018 Dec; 458():148-155. PubMed ID: 30218648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between the immune system and cancer: a brief review of non-spatial mathematical models.
    Eftimie R; Bramson JL; Earn DJ
    Bull Math Biol; 2011 Jan; 73(1):2-32. PubMed ID: 20225137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do tumors actively escape from host immunosurveillance?
    Wilczyński JR; Duechler M
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis.
    Müller-Hermelink N; Braumüller H; Pichler B; Wieder T; Mailhammer R; Schaak K; Ghoreschi K; Yazdi A; Haubner R; Sander CA; Mocikat R; Schwaiger M; Förster I; Huss R; Weber WA; Kneilling M; Röcken M
    Cancer Cell; 2008 Jun; 13(6):507-18. PubMed ID: 18538734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies of antigen-specific T-cell-based immunotherapy for cancer.
    Liu SH; Zhang M; Zhang WG
    Cancer Biother Radiopharm; 2005 Oct; 20(5):491-501. PubMed ID: 16248765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evasion of tumours from the control of the immune system: consequences of brief encounters.
    Al-Tameemi M; Chaplain M; d'Onofrio A
    Biol Direct; 2012 Sep; 7():31. PubMed ID: 23009638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-mediated dormancy: an equilibrium with cancer.
    Teng MW; Swann JB; Koebel CM; Schreiber RD; Smyth MJ
    J Leukoc Biol; 2008 Oct; 84(4):988-93. PubMed ID: 18515327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.